Author:
Berghauser Pont L M E,Balvers R K,Kloezeman J J,Nowicki M O,van den Bossche W,Kremer A,Wakimoto H,van den Hoogen B G,Leenstra S,Dirven C M F,Chiocca E A,Lawler S E,Lamfers M L M
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference63 articles.
1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.
3. Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Yung W, Sawaya R et al. First-in-human phase I clinical trial of oncolytic delta-24-rgd (dnx-2401) with biological endpoints: implications for viro-immunotherapy. Neuro Oncol 2014; 16 (Suppl 3): iii39.
4. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736–5742.
5. Kaufmann JK, Chiocca EA . Oncolytic virotherapy for gliomas: steps toward the future. CNS Oncol 2013; 2: 389–392.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献